Autonomix Medical, Inc.
No SEC Form 4 filings for $AMIX in the last 30 days.
See all $AMIX insider activity →Autonomix Medical (NASDAQ:AMIX) said it completed a Good Laboratory Practice pre-clinical study for its Autonomix platform, generating safety and performance data in porcine models across multiple anatomical targets, according to the company. The results are expected to support planned FDA submissions as part of its regulatory package.
Autonomix Medical (NASDAQ: AMIX) said it completed a GLP pre-clinical study evaluating safety, functionality, and performance of its nerve-targeted platform in porcine models. The company reported final histopathology and lab results supporting prior positive findings and said the data are expected to support its FDA submission regulatory package.
Autonomix Medical Inc. (AMIX) shares fell about 33.85% as dilution and warrant-related supply concerns weighed on sentiment. The company filed a prospectus for resale of up to 857,462 shares and previously completed a warrant inducement deal raising about $2.6M. AMIX also reported about $7.0M cash and no long-term debt, but ongoing operating cash outflows.
Over the past 7 days, alphai's AI scored 2 news stories mentioning AMIX (Autonomix Medical, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent AMIX coverage spans technology, corporate actions and market movers.
GLP pre-clinical completion is a regulatory-process milestone that can de-risk the FDA submission timeline, but it is not an approval or clinical outcome.
Completion of a GLP pre-clinical milestone is a positive regulatory step that can de-risk the FDA submission process, though it does not confirm FDA acceptance or clinical outcomes.
Expect continued high volatility and sell-pressure risk as incremental float supply from resale and warrants can cap squeezes.
The patent adds IP protection around its precision neuromodulation platform, which can support valuation and competitive positioning but is not an immediate revenue catalyst.
Patent expansion is a tangible IP catalyst that can re-rate risk and valuation, but the move is extreme and may mean high reversal risk.
alphai scores every news story that mentions AMIX with an AI model for sentiment and relevance, and aggregates insider trades from Autonomix Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Autonomix Medical (NASDAQ:AMIX) said it completed a Good Laboratory Practice pre-clinical study for its Autonomix platform, generating safety and performance data in porcine models across multiple anatomical targets, according to the company. The results are expected to support planned FDA submissions as part of its regulatory package.
4 min readAutonomix Medical (NASDAQ: AMIX) said it completed a GLP pre-clinical study evaluating safety, functionality, and performance of its nerve-targeted platform in porcine models. The company reported final histopathology and lab results supporting prior positive findings and said the data are expected to support its FDA submission regulatory package.
3 min readAutonomix Medical Inc. (AMIX) shares fell about 33.85% as dilution and warrant-related supply concerns weighed on sentiment. The company filed a prospectus for resale of up to 857,462 shares and previously completed a warrant inducement deal raising about $2.6M. AMIX also reported about $7.0M cash and no long-term debt, but ongoing operating cash outflows.
6 min readAutonomix Medical (AMIX) said the U.S. Patent No. 12,433,670 was issued for systems that sense, map, and selectively target nerves tied to tumors, cancer pain, and autonomic disorders. The patent covers catheter-based tools that record neural signals and deliver energy or agents. AMIX cited IP expansion. AMIX closed at $19.50, up 434.25% Tuesday.
2 min readU.S. indexes rose Tuesday. The article highlights retail-trader attention on several stocks. SpaceX-linked SPCX jumped 9.43% after Starlink subscribers doubled to 12M and cash/backlog were cited. AMD gained 7% on guidance for Q3 revenue around $13B. NVDA was mentioned via Musk comments. ALAB rose after a Q2 EPS and revenue beat. AMIX surged 434% on a new U.S. patent.
7 min readAutonomix Medical (NASDAQ:AMIX) shares rose 386.58% to $17.76 Tuesday after the company obtained a key cancer technology patent, according to Benzinga Pro. The patent covers catheter-based microsurgical tools for recording neural signals and delivering therapy, with claims across multiple cancer types, according to the company.
3 min readAutonomix Medical (NASDAQ:AMIX) shares rose 54.36% to $4.24 after hours Tuesday after a 1.43% intraday dip, closing at $2.75. Volume hit 10.60M shares, 24.14x average. The company filed to register 857,462 shares for resale from Series D warrants ($5.75 exercise), covering up to $3.72M, with potential $4.9M proceeds. It also reported about $5.1M cash and 971,043 shares outstanding, plus recent positive preclinical renal nerve ablation data.
4 min readAutonomix Medical Inc. (NASDAQ: AMIX) shares fell about 7% as investors weighed a $2.6M warrant inducement. The company said it enabled immediate exercise of 428,731 existing warrants at a $6.00 strike and issued replacement long-dated warrants, raising dilution concerns. The stock has dropped from the mid-$6s to around $3.29.
4 min readAutonomix Medical, Inc. (AMIX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ex_988125.htm EXHIBIT 4.1 ex_988125.htm Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FR
2 min readAutonomix Medical, Inc. (NASDAQ: AMIX) said the U.S. Patent and Trademark Office issued U.S. Patent No. 12,611,134 for a catheter-based platform to diagnose and treat overactive bladder. The company estimates the condition affects about 37 million Americans. Autonomix said its IP portfolio now includes 112 issued or pending applications worldwide.
3 min read
